CN101797263B - 一种抗菌消炎的中药组合物 - Google Patents
一种抗菌消炎的中药组合物 Download PDFInfo
- Publication number
- CN101797263B CN101797263B CN2010101098901A CN201010109890A CN101797263B CN 101797263 B CN101797263 B CN 101797263B CN 2010101098901 A CN2010101098901 A CN 2010101098901A CN 201010109890 A CN201010109890 A CN 201010109890A CN 101797263 B CN101797263 B CN 101797263B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- rhizoma coptidis
- radix scutellariae
- caulis fibraureae
- baicalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 230000003115 biocidal effect Effects 0.000 title abstract description 10
- 239000002131 composite material Substances 0.000 title abstract 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 27
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 27
- 229960003321 baicalin Drugs 0.000 claims abstract description 27
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940093265 berberine Drugs 0.000 claims abstract description 25
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 12
- RLQYRXCUPVKSAW-UHFFFAOYSA-M 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=C1 RLQYRXCUPVKSAW-UHFFFAOYSA-M 0.000 claims description 26
- RIDQRIPSFYHEGL-UHFFFAOYSA-N fibrauretin Natural products CC12CC=C3C(=O)OC(CC3(C)C1C(=O)C=CC2=O)c4cocc4 RIDQRIPSFYHEGL-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 3
- 239000004615 ingredient Substances 0.000 description 24
- 238000005303 weighing Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 3
- 206010033971 Paratyphoid fever Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 150000003836 berberines Chemical class 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 动物数 | 剂量(g/kg) | 小鼠扭体次数(次/20min) |
空白对照阿斯匹林本发明低剂量组本发明中剂量组本发明高剂量组 | 1212121212 | -0.10.20.40.8 | 40.4±11.715.6±9.8**31.4±12.124.7±10.919.2±12.5** |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101098901A CN101797263B (zh) | 2007-01-11 | 2007-01-11 | 一种抗菌消炎的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101098901A CN101797263B (zh) | 2007-01-11 | 2007-01-11 | 一种抗菌消炎的中药组合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710007803XA Division CN101032558B (zh) | 2006-01-12 | 2007-01-11 | 一种抗菌消炎的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101797263A CN101797263A (zh) | 2010-08-11 |
CN101797263B true CN101797263B (zh) | 2011-11-30 |
Family
ID=42593203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101098901A Expired - Fee Related CN101797263B (zh) | 2007-01-11 | 2007-01-11 | 一种抗菌消炎的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101797263B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106166182A (zh) * | 2016-06-29 | 2016-11-30 | 浙江圣博康药业有限公司 | 一种虫草复合胶囊 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1517095A (zh) * | 2003-01-14 | 2004-08-04 | 吉林天药科技股份有限公司 | 一种抗感染药物 |
CN1602886A (zh) * | 2003-09-29 | 2005-04-06 | 成都三明药物研究所 | 一种药物组合物及其用途 |
CN1839867A (zh) * | 2006-01-11 | 2006-10-04 | 四川省中药研究所 | 具有清热、泻火和解毒作用的药物组合物 |
-
2007
- 2007-01-11 CN CN2010101098901A patent/CN101797263B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1517095A (zh) * | 2003-01-14 | 2004-08-04 | 吉林天药科技股份有限公司 | 一种抗感染药物 |
CN1602886A (zh) * | 2003-09-29 | 2005-04-06 | 成都三明药物研究所 | 一种药物组合物及其用途 |
CN1839867A (zh) * | 2006-01-11 | 2006-10-04 | 四川省中药研究所 | 具有清热、泻火和解毒作用的药物组合物 |
Non-Patent Citations (2)
Title |
---|
唐斌等.黄连素的联合用药.《药学实践杂志》.2005,第23卷(第5期),第278页左栏第1段. * |
崔双荣等.黄连的配伍应用.《河北中医》.2003,第25卷(第10期),第758页右栏第8段. * |
Also Published As
Publication number | Publication date |
---|---|
CN101797263A (zh) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100594031C (zh) | 一种含片及其制备方法 | |
CN100372561C (zh) | 治疗口腔炎症的中药制剂及其制备方法 | |
CN102204971B (zh) | 一种防治口腔、咽喉疾病的中药制剂 | |
CN102485253A (zh) | 一种清热解毒凉血通淋的中药组合物及制备方法 | |
CN101664446A (zh) | 热淋清浸膏及其制备方法和用途 | |
CN100356944C (zh) | 一种具有止咳平喘功能的药物 | |
CN104013846A (zh) | 一种治疗口腔溃疡的中药组合物及其应用 | |
CN101618146A (zh) | 一种用于治疗上呼吸道感染的复方中药制剂及其制备方法 | |
CN101406629A (zh) | 一种用于治疗牙龈肿痛的口含片及其制备方法 | |
CN102119994B (zh) | 一种治疗小儿外感发热的中药灌肠液 | |
CN101797263B (zh) | 一种抗菌消炎的中药组合物 | |
CN103816281B (zh) | 一种预防和治疗风热感冒的中药组合物 | |
CN101032558B (zh) | 一种抗菌消炎的中药组合物 | |
CN103845633B (zh) | 一种治疗口腔溃疡的中药组合物及其制备方法 | |
CN101002874B (zh) | 一种抗菌消炎复方中药及其制备方法 | |
CN101112554A (zh) | 治疗妇科疾病的薄膜衣片及其制备方法 | |
CN1899392B (zh) | 一种用于治疗妇科炎症的中药组合物及其制备方法和应用 | |
CN100563677C (zh) | 一种清咽中药制剂 | |
CN101574422B (zh) | 一种药物组合物及其制备方法 | |
CN101007062B (zh) | 一种抗感染中药组合物 | |
CN101310735B (zh) | 一种清热,解毒、消炎的中药颗粒剂及其制备方法 | |
CN1273155C (zh) | 一种治疗急性咽炎的中药口服制剂 | |
CN103961654B (zh) | 一种白葡萄球菌片及其制备方法 | |
CN103463401B (zh) | 小儿用哮喘药 | |
CN101239103A (zh) | 一种清热解毒的中药制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN JIUDIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHU ZHIHONG Effective date: 20111008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Zhihong Inventor after: Bu Zhenjun Inventor after: Yang Jing Inventor before: Zhu Zhihong |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHU ZHIHONG TO: ZHU ZHIHONG BU ZHENJUN YANG JING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20111008 Address after: 410004, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Applicant after: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. Address before: 410004, Hunan, Changsha province Furong South Road section 368 BOBO world city CTA wealth center, 24 floor Applicant before: Zhu Zhihong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee after: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. Address before: 410004, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee before: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 410205 8th floor, building A1, Lugu science and Technology Industrial Park, Wukuang, No.28, Ludian Road, Yuelu District, Changsha City, Hunan Province Patentee after: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. Address before: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee before: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No.1, Jiankang Avenue, Liuyang Biomedical Park, Liuyang City, Changsha City, Hunan Province Patentee after: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. Address before: 410205 8th floor, building A1, Lugu science and Technology Industrial Park, Wukuang, No.28, Ludian Road, Yuelu District, Changsha City, Hunan Province Patentee before: HUNAN JIUDIAN PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111130 Termination date: 20220111 |